Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Pleiotropic prodrugs“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Pleiotropic prodrugs" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Pleiotropic prodrugs"
Li, Jiaqi. „Advances and applications of prodrug strategies in drug design“. Journal of Food Science, Nutrition and Health 3, Nr. 1 (18.11.2024): 12–22. https://doi.org/10.54254/3029-0821/3/2024023.
Der volle Inhalt der QuelleToublet, François-Xavier, Cédric Lecoutey, Julien Lalut, Bérénice Hatat, Audrey Davis, Marc Since, Sophie Corvaisier et al. „Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer’s Disease“. Molecules 24, Nr. 15 (31.07.2019): 2786. http://dx.doi.org/10.3390/molecules24152786.
Der volle Inhalt der QuelleChirumbolo, Salvatore, Geir Bjørklund, Roman Lysiuk, Antonio Vella, Larysa Lenchyk und Taras Upyr. „Targeting Cancer with Phytochemicals via Their Fine Tuning of the Cell Survival Signaling Pathways“. International Journal of Molecular Sciences 19, Nr. 11 (12.11.2018): 3568. http://dx.doi.org/10.3390/ijms19113568.
Der volle Inhalt der QuelleCampos-Salinas, Jenny, Margarita Barriga und Mario Delgado. „Therapeutic Effect of a Latent Form of Cortistatin in Experimental Inflammatory and Fibrotic Disorders“. Pharmaceutics 14, Nr. 12 (13.12.2022): 2785. http://dx.doi.org/10.3390/pharmaceutics14122785.
Der volle Inhalt der QuelleToublet, François-Xavier, Julien Lalut, Bérénice Hatat, Cédric Lecoutey, Audrey Davis, Marc Since, Sophie Corvaisier et al. „Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer’s disease“. European Journal of Medicinal Chemistry 210 (Januar 2021): 113059. http://dx.doi.org/10.1016/j.ejmech.2020.113059.
Der volle Inhalt der QuelleLeitsch, David. „A review on metronidazole: an old warhorse in antimicrobial chemotherapy“. Parasitology 146, Nr. 9 (23.11.2017): 1167–78. http://dx.doi.org/10.1017/s0031182017002025.
Der volle Inhalt der QuelleBettendorff, Lucien. „Synthetic Thioesters of Thiamine: Promising Tools for Slowing Progression of Neurodegenerative Diseases“. International Journal of Molecular Sciences 24, Nr. 14 (10.07.2023): 11296. http://dx.doi.org/10.3390/ijms241411296.
Der volle Inhalt der QuelleNirschl, Christopher J., Pam Alderhold, Heather R. Brodkin, Connor J. Dwyer, Daniel J. Hicklin, Nesreen Ismail, Andres Salmeron et al. „Abstract 2055: WTX-330 is a conditionally activated IL-12 prodrug that fundamentally reprograms tumor infiltrating CD8+ T cells and drives tumor regression“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 2055. http://dx.doi.org/10.1158/1538-7445.am2022-2055.
Der volle Inhalt der QuelleSu, Qingtai, Stephen Gutowski, Austin Burcham, Bhargavi Allu, Zirong Chen, Fiona Stavros, Ruolan Han, Jason B. Miller und Tian Zhao. „Abstract LB438: Preclinical characterization of ONM-412, an ultra-pH sensitive nanoparticle encapsulated IL-12 fusion protein“. Cancer Research 84, Nr. 7_Supplement (05.04.2024): LB438. http://dx.doi.org/10.1158/1538-7445.am2024-lb438.
Der volle Inhalt der Quelle„Vitamin-D-Hormon-Prodrug Alfacalcidol - Die pleiotrope Therapieoption bei renaler Osteopathie“. Dialyse aktuell 12, Nr. 08 (01.12.2008): 513. http://dx.doi.org/10.1055/s-0028-1104656.
Der volle Inhalt der QuelleDissertationen zum Thema "Pleiotropic prodrugs"
Toublet, Francois-Xavier. „Conception, synthèse et évaluation biologique de prodrogues pléiotropes d'intérêt dans la maladie d'Alzheimer“. Thesis, Normandie, 2019. http://www.theses.fr/2019NORMC429.
Der volle Inhalt der QuelleAlzheimer’s disease (AD) is a multifactorial neurodegenerative disease which is still poorly understood. The drugs currently used against AD, mainly cholinesterase inhibitors (ChEI), are considered clinically insufficient and are responsible for deleterious side effects. ChE are, however, currently receiving renewed interest through the discovery of a chaperone role played in the pathogenesis of AD. But ChE could also serve as an activating protein for pleiotropic prodrugs. Indeed, inhibiting central ChE with brain-penetrating designed carbamates which are able to covalently bind to the enzyme and to concomitantly liberate active metabolites in the brain could constitute a clinically more efficient approach which, additionally, is less likely to cause peripheral side effects.This thesis has opened up new synthetic pathways, coupled with in vitro and in vivo studies of pleiotropic prodrugs targeting both AChE and BuChE with another therapeutic target such as 5-HT4 and / or 5-HT6 serotoninergic receptors. But also the study new compounds very interesting and never yet describes: pleiotropic self-immolative linkers.This plural activity could bring to AD patients effective, relatively safe, symptomatic and disease-modifying therapeutic benefits
Wang, Alice. „Cοnceptiοn, synthèse et évaluatiοn biοlοgique de nοuveaux prοmédicaments d'intérêt thérapeutique pοtentiel pοur le traitement de la maladie d'Alzheimer et du syndrοme de Dοwn assοcié“. Electronic Thesis or Diss., Normandie, 2024. http://www.theses.fr/2024NORMC233.
Der volle Inhalt der QuelleStudies have shown that people with Down's syndrome (DS) or trisomy 21 have a higher risk of developing dementia due to Alzheimer's disease (AD). In fact, certain common therapeutic targets have been identified in these two multifactorial diseases, for which no effective treatment currently exists. In order to simultaneously treat these common origins, the approach of multi-target directed ligands (MTDLs) seems promising. These compounds combine in a single structure several biological activities targeting various molecular causes involved in the disease. The aim is to achieve a synergistic effect and reduce side effects in the context of a chronic disease requiring lifelong treatment. During this work, chemical synthesis routes have been optimized to obtain some twenty pleiotropic prodrugs. These compounds have shown promising in vitro activity on cholinesterases, serotonin receptors, adrenergic receptors or HMGB1 protein, four important targets in AD and/or associated with DS. The inhibition mechanism of cholinesterases and the effect of prodrugs on cellular model were evaluated. Permeability and druggability parameters were also determined to identify prodrugs administration route. These studies provided initial structure-activity relationship (SAR) data for the three targets, enabling us to identify the most promising candidate for in vivo studies in AD mice through intranasal administration